Tune in today at 1pm ET to listen as Jeff Baxter, President & CEO, and David E. Anderson, Chief Scientific Officer, discuss our #HBV portfolio with covering analyst, Steven Seedhouse, Ph.D., of Raymond James & Associates, Inc. Access the link here: bit.ly/3mf8uqY $VBIV

ICYMI: Jeff Baxter, CEO, & David E Anderson, CSO, recently sat down with analyst Steven Seedhouse, Ph.D., of Raymond James and Associates to discuss encouraging initial Phase 2 data from our #HBV immunotherapeutic candidate, VBI-2601. Access the replay: bit.ly/3KPelgR

Today we announced the launch of our 3-antigen prophylactic #HBV vaccine in the Netherlands & Belgium through our partnership with Valneva. Together with our partners, we continue to take important steps in the public health battle against #HepB worldwide $VBIV

This #GBMDay, we are proud to partner with National Brain Tumor Society to raise awareness for patients with this aggressive cancer who need additional treatment options. $VBIV #Glioblastoma

We are proud to support the global public health battle against #HepB through our commitment to address both prevention & treatment. Together with World Hepatitis Alliance, join us in raising awareness this #WorldHepatitisDay and learn more here: bit.ly/3qbQAre #HepCantWait

$VBIV in the News: Today we shared interim Phase 1 results for VBI-2901 – representing the first data in the field from a pan-coronavirus vaccine candidate to show broadened & durable immune responses against both human & animal coronaviruses #COVID19 on.mktw.net/48wDQgf

Though a rare disease, #glioblastoma accounts for nearly half of all malignant brain tumors with an estimated 12,000 people diagnosed annually in the U.S. Today and every day we strive to provide new treatment options for patients with #GBM. #RareDiseaseDay $VBIV @rarediseases

We are grateful to announce an expanded collaboration with the Canadian government, supported by CAD$28 million funding remaining under our original agreement. We look forward to continuing our partnership to accelerate the development of our MLE platform. bit.ly/3vEfdji

Today, David E. Anderson, PhD, VBI's CSO, presented encouraging early tumor response data from the Phase 2b study of VBI-1901 in recurrent #GBM at World Vaccine Congress's World Vaccine Congress 2024. Read more about the data here: bit.ly/4cKzzYA #WVCDC

This morning, we announced full year 2023 financial results in addition to recent business highlights and upcoming milestones. Read the full update here: bit.ly/4cW6gCB $VBIV

VBI celebrates vaccination as the frontline of protection against disease & as a cost-effective public health intervention. Read Office of Health Economics' report on the health & socio-economic benefits of immunization programs here: bit.ly/4dcpofK #WorldImmunizationWeek #VaccinesForLife

The CDC Hepatitis estimates that as many as 2.2 million people are chronically infected with #HBV in the U.S., but only 30% of adults are fully vaccinated. Understand the risks of infection and know your vaccination options this #AdultHepBVaxDay.

This #BrainTumorAwarenessMonth, we support the brain tumor community and shine a light on the impact these difficult diagnoses have on patients, families, and caretakers. Help us raise awareness as we #GoGrayInMay

#DYK that hepatitis B is a vaccine-preventable liver disease and that the CDC Hepatitis recommends all adults ages 19-59 should be vaccinated against #HBV? May is #HepatitisAwarenessMonth – learn the ABCs of Viral Hepatitis here: bit.ly/4aMFGdA

We are pleased to share that new interim data from our randomized, controlled Phase 2b study of VBI-1901 in recurrent #glioblastoma will be presented at #ASCO24. Learn more here: bit.ly/3V90Xc9 ASCO #GBM #BrainTumorAwarenessMonth

This #HepatitisAwarenessMonth, we are highlighting the millions of individuals infected with #HBV. Prevention is possible through testing and vaccination. Learn more about the @CDC’s adult hepatitis B vaccination guidelines here: bit.ly/3WUQuCq

Today, we announced new & encouraging data from our Phase 2b study of VBI-1901 in recurrent #glioblastoma will be presented at #ASCO24 this Saturday. We look forward to advancing this program and continuing our fight against #GBM. Read full details here: bit.ly/4bXXiDo

With few approved treatment options, we’re working to change the odds for #glioblastoma patients. ICYMI, VBI is presenting new and encouraging data from our VBI-1901 program in recurrent #GBM at #ASCO24 on Saturday, June 1. Read more here: bit.ly/4bXXiDo #BTAM

#DYK our cancer vaccine candidate, VBI-1901, is an immunotherapy? Learn more about how VBI is harnessing the power of the body’s innate immune response to fight #glioblastoma this #CancerImmunotherapyMonth: vbivaccines.com/our-pipeline/

Today we celebrate #WorldHepatitisDay and shine a light on the millions of people battling #hepatitisB around the globe. Join us and World Hepatitis Alliance in raising awareness for the fight against #HBV.